



FOR IMMEDIATE RELEASE

NEWS

Contact: D. Lansing Taylor
President & CEO
Cellumen, Inc.
(412) 481-5690

Chemicon International and Cellumen Announce an R & D Agreement to Commercialize a Systems Cell Biology Approach to Cytotoxicity Profiling in Drug Discovery

ATLANTA, GA – February 7, 2006 – Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, has entered into a research and development agreement with Cellumen, Inc., to commercialize a cytotoxicity profiling panel and services designed with Chemicon and Upstate’s market-leading cellular assay reagents and Cellumen’s system cell biology approach. Chemicon will focus on the development and production of the resulting assays and panels, while Cellumen will focus on their use in profiling services and knowledge generation . The companies will jointly market these solutions to the pharmaceutical industry.

“We are pleased to combine our expertise in reagent technologies with the systems cell biology approach being pioneered by Cellumen,” stated Jeffrey D. Linton, President of Chemicon and Upstate, which comprise Serologicals’ Research Segment. “The use of cellular systems to profile toxic responses at the earliest stages in drug development will enhance the ability of our Pharmaceutical customers to select appropriate compounds for further development and represents a major opportunity to address the attrition rate in the process. We are committed to bringing the highest quality reagents and services to the life sciences market to address the major challenges in basic research, and drug development.”

“Systems cell biology is the study of the cell as the basic unit of life: an *integrated* and *interacting* network of genes, proteins and biochemical reactions which give rise to functions and life,” stated D. Lansing Taylor, Ph. D., CEO of Cellumen, Inc. “Cytotoxicity

must be viewed as a systems response and not just the response of a few cellular constituents. There is great potential to have a systems cell biology profile that will be predictive of the human toxic response. This is a major challenge in the drug development process.”

Chemicon Announces Agreement with Cellumen to Commercialize Approach to Cytotoxicity Profiling in Drug Discovery

Chemicon International, Inc. offers a broad range of research products, including specialty reagents, kits, antibodies, and custom products and services, to customers working in the areas of neuroscience, stem cell biology, cancer, and infectious disease research. It is also a leading supplier of monoclonal antibodies, conjugates, antibody blends and molecular-based detection kits for use in diagnostic laboratories. Chemicon focuses on basic and biomedical research, drug discovery, and diagnostics, allowing it to serve thousands of customers worldwide in the academic, clinical, biotechnology, and pharmaceutical sectors. Acquired in 2003, Chemicon is a Serologicals company, based in Temecula, CA.

For more information, please visit our website: www.chemicon.com

Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta, GA., is a global leader in developing and commercializing consumable biological products, enabling technologies and services in support of biological research, drug discovery, and the bioprocessing of lifeenhancing products. Our customers include researchers at major life science companies and leading research institutions involved in key disciplines, such as neurology, oncology, hematology, immunology, cardiology, proteomics, infectious diseases, cell signaling and stem cell research. In addition, Serologicals is the world’s leading provider of monoclonal antibodies for the blood typing industry. Serologicals employs a total of more than 1,000 people worldwide in three Serologicals’ companies: Chemicon International, headquartered in Temecula, CA, Upstate Group, LLC, headquartered in Charlottesville, VA. and Celliance Corporation, headquartered in Atlanta, GA.

For more information, please visit our website: www.serologicals.com

About Cellumen Inc.: Cellumen is a systems cell biology company that performs collaborative discovery programs with pharmaceutical, biotechnology and personalized medicine companies. Powerful cellular models of disease and integrated function are created using proprietary reagents that measure and manipulate cellular constituents. The systems cell biology approach integrates high throughput and high content analyses with proprietary informatics tools to create a profile of systemic function and dysfunction.

For more information, please visit www.cellumen.com

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words or phrases such as “should result,” “are expected to,” “we anticipate,” “we estimate,” “we project” or similar expressions are intended to identify forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. You should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made, and the Company undertakes no obligation to update these statements based on events that may occur after the date of this press release.

Serologicals is a registered trademark of Serologicals Royalty Company.
-- END --